Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota

International Journal of Antimicrobial Agents

Volumn 29, Issue 1, 2007, Pages 66-72

  Myllyluoma, E ^a,b   Ahlroos, T ^c   Veijola, L ^d,e   Rautelin, H ^d,f   Tynkkynen, S ^c   Korpela, R ^a,b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FOUNDATION FOR NUTRITION RESEARCH   (Finland)

^c VALIO LTD   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e Herttoniemi Hospital   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Clinical trial; Eradication therapy; Helicobacter pylori; Intestinal microbiota; Probiotics

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; PLACEBO; PROBIOTIC AGENT;

ADULT; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BIFIDOBACTERIUM BREVE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENTEROCOCCUS; ERADICATION THERAPY; FECES CULTURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS RHAMNOSUS; MALE; PRIORITY JOURNAL; PROPIONIBACTERIUM FREUDENREICHII; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; BIFIDOBACTERIUM; CELL COUNT; CLARITHROMYCIN; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FECES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINES; LACTOBACILLUS RHAMNOSUS; MALE; MIDDLE AGED; PROBIOTICS; PROPIONIBACTERIUM; TREATMENT OUTCOME;

EID: 33845606681     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.08.034     Document Type: Article

References (30)

1. International Agency for Research on Cancer. Schistosomes, liver flukes, and Helicobacter pylori. 1994 IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 61. Lyon, France: IARC; 1994. p. 1-239.
2. Malfertheiner P., Megraud F., O'Morain C., et al., European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16 (2002) 167-180
3. McLoughlin R., Racz I., Buckley M., O'Connor H.J., and O'Morain C. Therapy of Helicobacter pylori. Helicobacter 9 (2004) 42-48
4. Nord C.E., Kager L., and Heimdahl A. Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections. Am J Med 15 (1984) 99-106
5. Norrby S.R. Ecological consequences of broad spectrum versus narrow spectrum antibacterial therapy. Scand J Infect Dis Suppl 49 (1986) 189-195
6. Hoiby N. Ecological antibiotic policy. J Antimicrob Chemother 46 Suppl. 1 (2000) 59-62
7. Sjolund M., Wreiber K., Andersson D.I., Blaser M.J., and Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 139 (2003) 483-487
8. Vollaard E.J., and Clasener H.A.L. Colonization resistance. Antimicrob Agents Chemother 38 (1994) 409-414
9. Sullivan A., Edlund C., and Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 1 (2001) 101-114
10. Madden J.A.J., Plummer S.F., Tang J., et al. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study. Int Immunopharmacol 5 (2005) 1091-1097
11. Plummer S.F., Garaiova I., Sarvotham T., et al. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int J Antimicrob Agents 26 (2005) 69-74
12. Adamsson I., Nord C.E., Lundquist P., Sjöstedt S., and Edlund C. Comparative effects of omeprazole, amoxicillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother 44 (1999) 629-640
13. Bühling A., Radun D., Müller W.A., and Malferhteiner P. Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. Aliment Pharmacol Ther 15 (2001) 1445-1452
14. Simon G.L., and Gorbach S.L. Intestinal flora in health and disease. Gastroenterology 86 (1984) 174-193
15. Marteau P., Seksik P., and Jian R. Probiotics and intestinal health effects: a clinical perspective. Br J Nutr 88 Suppl. 1 (2002) S51-S57
16. Myllyluoma E., Veijola L., Ahlroos T., et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy-a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 21 (2005) 1263-1272
17. Kajander K., Hatakka K., Poussa T., Färkkilä M., and Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22 (2005) 387-394
18. Franks A.H., Harmsen H.J.M., Raangs G.C., Jansen G.J., Schut F., and Welling G.W. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol 64 (1998) 3336-3345
19. Langendijk P.S., Schut F., Jansen G.J., et al. Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in faecal samples. Appl Environ Microbiol 61 (1995) 3069-3075
20. Harmsen H.J.M., Elfferich P., Schut F., and Welling G.W. A 16S rRNA-targeted probe for detection of lactobacilli and enterococci in faecal samples by fluorescent in situ hybridization. Microb Ecol Health Dis 11 (1999) 3-12
21. Suau A., Rochet V., Sghir A., et al. Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora. Syst Appl Microbiol 24 (2001) 139-145
22. Vedamuthu E.R., Raccach M., Glatz B.A., Seitz E.W., and Reddy M.S. Acid producing microorganism. In: Vanderzant C., and Splittstoesser D.F. (Eds). Compendium of methods for the microbiological examination of foods (1992), APHA, Washington, DC 225-238
23. Brismar B., Edlund C., and Nord C.E. Comparative effects of clarithromycin and erythromycin on the normal intestinal microflora. Scand J Infect Dis 23 (1991) 635-642
24. Endlund C., and Nord C.E. Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections. J Antimicrob Chemother 46 Suppl. 1 (2000) 41-48
25. Matute A.J., Schurink C.A., Krijnen R.M., Florijn A., Rozenberg-Arska M., and Hoepelman I.M. Double-blind, placebo-controlled study comparing the effect of azithromycin with clarithromycin on oropharyngeal and bowel microflora in volunteers. Eur J Clin Microbiol Infect Dis 21 (2002) 427-431
26. Stark C.A., Adamsson I., Endlund C., et al. Effects of omeprazole and amoxicillin on the human oral and gastrointestinal microflora in patients with Helicobacter pylori infection. J Antimicrob Chemother 38 (1996) 927-939
27. Lode H., Von der Hoh N., Ziege S., Borner K., and Nord C.E. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis 33 (2001) 899-903
28. Hartemink R., and Rombouts F.M. Comparison of media for the detection of bifidobacteria, lactobacilli and total anaerobes from faecal samples. J Microbiol Methods 36 (1999) 181-192
29. McCartney A.L. Application of molecular biological methods for studying probiotics and the gut flora. Br J Nutr 88 Suppl. 1 (2002) S29-S37
30. Isolauri E., Salminen S., and Ouwehand A.C. Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol 18 (2004) 299-313